Merck (MRK) Completes Acquisition of EyeBio

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ENPH
2. HOOD
3. NXPI
4. SPY
5. BA
6. STX
7. NOW
8. GOOGL
9. V
10. CSGP

Go back to Merck (MRK) Completes Acquisition of EyeBio

Merck Completes Acquisition of EyeBio

July 12, 2024 6:45 AM EDT

Acquisition strengthens and diversifies Mercks pipeline with the addition of Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration, as well as preclinical candidates

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of Eyebiotech Limited (EyeBio). EyeBio is now a wholly-owned subsidiary of Merck.

The EyeBio acquisition further diversifies our late-stage pipeline with the addition of a promising candidate based on novel biology and... More